American pharmaceutical company Johnson & Johnson revealed Wednesday that it would expedite the development of its vaccine for SARS-CoV-2, the virus that causes…
In a June 10 news release, the company’s Vice Chairman of the Executive Committee and Chief Scientific Officer Paul Stoffels wrote, “Based on the strength of the preclinical data we have seen so far and interactions with the regulatory authorities, we have been able to further accelerate the clinical development of our investigational SARS-CoV-2 vaccine, Ad26. COV2-S, recombinant.”
The human trials in July will be randomized, double-blind and placebo-controlled and will test the drug’s safety, reactogenicity (or ability to produce common adverse reactions like fever or soreness at the injection site) and immunogenicity (or ability to induce an immune system response).
